PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
EO2401, a pioneering OncoMimics„ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens...
Enterome Announces Presentation on OncoMimics Approach to Cancer Immunotherapy
PARIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...
Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual Meeting Median survival of 14.5 months and 18-months survival rate of 43.1% in a 26-patient cohort where EO2401 was...
PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors (SPENCER) and in recurrent glioblastoma (ROSALIE) High degree of homology with TAAs and robust immune responses validate the...
LLS TAP is a strategic funding initiative to accelerate innovative blood cancer therapeutics Strategic equity investment of ‚¬3 million to support clinical advancement of EO2463 in Non-Hodgkin™s...
PARIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...
Updated results demonstrate sustained efficacy with a good safety profile Degree of tumor shrinkage on CT scans correlates with strength of CD8+ T cell specific immune response against EO2401...